Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder - Full Text View

Sponsored by:	Massachusetts General Hospital
Information provided by:	Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00592852

Purpose

This will be a 12-week open-label pilot treatment study for children and adolescents (ages 6-17) who meet DSM-IV criteria for bipolar disorder (BPD) and obsessive-compulsive disorder (OCD) who are adequately mood stabilized on a stable regimen based on standard clinical care. Specific hypotheses are as follows:

Hypothesis 1: Children and adolescents with comorbid OCD and BPD who have achieved adequate mood stabilization using a naturalistic clinical practice approach, will benefit from an FDA-approved SSRI on their OCD symptoms in a clinically meaningful way without exacerbation of bipolar symptoms.

Condition	Intervention	Phase
Pediatric Bipolar Disorder Pediatric OCD	Drug: fluoxetine	Phase IV

MedlinePlus related topics: Bipolar Disorder Obsessive-Compulsive Disorder

Drug Information available for: Fluoxetine Fluoxetine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Single Group Assignment
Official Title:	A Pilot Treatment Study of Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:

CY-BOCs [ Time Frame: weekly ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

YMRS [ Time Frame: weekly ] [ Designated as safety issue: No ]

Estimated Enrollment:	20
Study Start Date:	December 2005
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: fluoxetine capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks

Detailed Description:

As no systemic data is available regarding the efficacy and safety of SSRI in the treatment of OCD+BPD children, it calls for a preliminary open pilot treatment study to explore these issues as a logical first step that could lead to systematic randomized controlled trials in the future. SSRI's are the first line and most commonly used anti-OCD agents. It remains unknown, which of the standard SSRIs is least activating for youth with BPD. Fluoxetine along with fluvoxamine and sertraline are FDA approved for the treatment of OCD in children. Fluoxetine remains the most extensively studied SSRI in children. We will test the safety and efficacy of fluoxetine in children and adolescents with BPD and OCD.

The proposed study includes 1.) the use of a 12-week design to document the response rate and 2.) careful assessment of safety and tolerability

Eligibility

Ages Eligible for Study:	6 Years to 17 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female participants between 6 and 17 years of age.
Participants must have DSM-IV diagnosis of OCD and bipolar (I or II) disorder, displaying current OCD symptoms of at least moderate impairment (CY-BOCS ≥ 15) and for at least 4 weeks prior to participation maintained on steady dose of mood stabilizing medication (lithium, anticonvulsants or atypical antipsychotics) with minimal or mild mood symptoms (YMRS ≤ 15). Period of mood stabilization will be determined by clinician judgment and confirmed by K-SADS-E.
Subject and his/her legal representative must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.
Subjects and his/her legal representative must be considered reliable.
Each subject and his/her authorized legal representative must understand the nature of the study. The subject's authorized legal representative and the subject must sign an IRB approved informed consent and assent document respectively.
Subject must be able to participate in mandatory blood draws.
Subject must be able to swallow pills.
Subjects with comorbid ADHD, ODD, CD, or other anxiety disorders will be allowed to participate in the study provided they do not meet any exclusionary criteria.

Exclusion Criteria:

DSM-IV substance dependence (except nicotine or caffeine) within past 3 months.
History of anti-depressant induced mania or hypomania while also being treated with appropriate dosage(s) of mood stabilizers.
Pregnant or nursing females.
Investigator and his/her immediate family, defined as the investigator's spouse, parent, child, grandparent, or grandchild.
Serious, unstable systemic illness.
History of severe allergies or multiple adverse drug reactions.
Non-febrile seizures without a clear and resolved etiology.
Clinically judged to be at serious suicidal risk.
Other concomitant medication with primary central nervous system activity other than those specified in the Concomitant Medication protocol.
History of allergic reaction to SSRIs.
Participants using an MAOI within two weeks prior to receiving study medication.
Current diagnosis of schizophrenia.
Uncorrected hypo or hyperthyroidism.
Active symptoms of anorexia or bulimia nervosa
Non-response of OCD symptoms to fluoxetine as defined by being on therapeutic dose of fluoxetine for at least 10 weeks.
Current treatment with antidepressant medication.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00592852

Contacts

Contact: Meghan Kotarski, BS

617-503-1051

mkotarski@partners.org

Locations

United States, Massachusetts
Massachusetts General Hospital	Recruiting
Cambridge, Massachusetts, United States, 02138

Sponsors and Collaborators

Massachusetts General Hospital

Investigators

Principal Investigator:

Gagan Joshi, MD

MGH

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	MGH ( Gagan Joshi, MD )
Study ID Numbers:	2005-P-001840
Study First Received:	December 28, 2007
Last Updated:	January 11, 2008
ClinicalTrials.gov Identifier:	NCT00592852 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:

bipolar disorder
obsessive compulsive disorder
Prozac

Study placed in the following topic categories:

Neurotransmitter Agents
Bipolar Disorder
Psychotropic Drugs
Serotonin Uptake Inhibitors
Serotonin
Fluoxetine
Affective Disorders, Psychotic

Anxiety Disorders
Mental Disorders
Mood Disorders
Psychotic Disorders
Antidepressive Agents, Second-Generation
Obsessive-Compulsive Disorder
Antidepressive Agents

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Disease
Molecular Mechanisms of Pharmacological Action
Bipolar Disorder
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Uptake Inhibitors
Pharmacologic Actions
Fluoxetine
Affective Disorders, Psychotic

Serotonin Agents
Pathologic Processes
Anxiety Disorders
Mental Disorders
Therapeutic Uses
Mood Disorders
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents
Obsessive-Compulsive Disorder

ClinicalTrials.gov processed this record on May 07, 2009